Who are KHK7580's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): KHK4827, C1 esterase inhibitor [human] liquid, KHK7791, BCX7353 capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/khk7580.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

KHK7580 — Competitive Intelligence Brief

KHK7580 (KHK7580) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor XIa inhibitor. Area: Cardiovascular.

phase 3 Factor XIa inhibitor Factor XIa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

KHK7580 (KHK7580) — Kyowa Kirin Co., Ltd.. KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KHK7580 TARGET	KHK7580	Kyowa Kirin Co., Ltd.	phase 3	Factor XIa inhibitor	Factor XIa
KHK4827	KHK4827	Kyowa Kirin Co., Ltd.	phase 3	Factor XIa inhibitor	Factor XIa
C1 esterase inhibitor [human] liquid	C1 esterase inhibitor [human] liquid	Shire	phase 3	Serine protease inhibitor; plasma-derived protein replacement	C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein
KHK7791	KHK7791	Kyowa Kirin Co., Ltd.	phase 3	Factor XIa inhibitor	Factor XIa
BCX7353 capsules	BCX7353 capsules	BioCryst Pharmaceuticals	phase 3	Plasma kallikrein inhibitor	Plasma kallikrein (Factor XIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor XIa inhibitor class)

Kyowa Kirin Co., Ltd. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KHK7580 — Competitive Intelligence Brief. https://druglandscape.com/ci/khk7580. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab